ISEE - Earnings announcements

IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its fourth quarter and full year 2022 financial and operating results on Wednesday, March 1, 2023. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update. To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 1375589. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours foll

- Reported Positive GATHER2 Results for Avacincaptad Pegol in Geographic Atrophy - - Planned NDA Submission Moved Up to End of This Year - - Received Favorable Feedback from FDA on Intermediate AMD Development Plan - - Conference Call and Webcast Today, November 3, 2022, at 8:00 a.m. ET - IVERIC bio, Inc. (NASDAQ:ISEE) today announced financial and operating results for the third quarter ended September 30, 2022 and provided a general business update. "With the positive data from our GATHER2 clinical trial reported in the third quarter reinforcing the positive data from GATHER1, avacincaptad pegol (ACP) became the first and only investigational therapy in geographic atrophy (GA) to ach

IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update. To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 8170771. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the liv

- Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area - - Statistically Significant Result with Favorable Safety Profile - - Post-hoc Analysis of U.S. Patients: 25.5% Reduction (p-value = 0.0037) Using Square Root Transformation; 32.0% Reduction (p-value = 0.0033) Using Observed GA Area - - Plan to Submit New Drug Application to the FDA by the End of the First Quarter 2023 - - Conference Call and Webcast Today, September 6, 2022 at 8:00am ET - IVERIC bio, Inc. (NASDAQ:ISEE) today announced positive topline results from GATHER2, th

- Zimura® GATHER2 Topline Data Expected in September of this Year- - GATHER2 Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate of 92.5% – - Agreement for up to $250 Million in Non-dilutive Debt Financing Secured - - Exclusive License Entered into for Sustained Release Delivery Technology for Zimura® - - Conference Call and Webcast Today, July 26, 2022, at 8:00 a.m. ET – IVERIC bio, Inc. (NASDAQ:ISEE) today announced financial and operating results for the second quarter ended June 30, 2022 and provided a general business update. "We are excited to share that today marks one year since we completed patient enrollment of GATHER2, our second Phase

IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its second quarter 2022 financial and operating results on Tuesday, July 26, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update. To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 0932671. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the live c

- Zimura® GATHER2 Topline Data Expected in the Third Quarter of this Year- - GATHER2 Trial Completion at 94% for Year One; Patient Retention Continues to Exceed Expectations with a Target 12-Month Injection Fidelity Rate of Greater than 90% – - U.S. Patent Covering Methods of Treating GA with Zimura Granted by USPTO – - Conference Call and Webcast Today, May 4, 2022, at 8:00 a.m. ET – IVERIC bio, Inc. (NASDAQ:ISEE) today announced financial and operating results for the first quarter ended March 31, 2022 and provided a general business update. "During the first quarter, we continued the momentum of 2021 for GATHER2, our second Phase 3 clinical trial for Zimura® (avacincaptad pegol), a

IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update. To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 1313914. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the live ca

IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, February 24, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update. To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 8865993. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours f

IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its third quarter 2021 financial and operating results on Tuesday, November 9, 2021. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update. To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 0259351. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the live

IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its second quarter 2021 financial and operating results on Wednesday, August 4, 2021. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update. To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 7257034. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the liv